KIA
ALXN

KCM Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

KCM Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-2,313
Closed -$269K – 454
2013
Q3 		$269K Buy
+2,313
New +$254K 0.03% 380

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

KCM Investment Advisors's ALXN Position: Q4 2013 in Review

KCM Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q4 2013, closing a stake of 2,313 shares — an estimated $269K sold.

KCM Investment Advisors first reported a position in ALXN in Q3 2013 and held it in 1 quarter. The position peaked at $269K in Q3 2013. 462 funds tracked by Wall St. Rank hold ALXN as of Q4 2013.

  • KCM Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • KCM Investment Advisors sold 2,313 Alexion Pharmaceuticals shares in Q4 2013, an estimated $269K.
  • KCM Investment Advisors first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • KCM Investment Advisors's Alexion Pharmaceuticals position peaked at $269K in Q3 2013.
  • 462 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2013.

Based on KCM Investment Advisors's 13F filing for Q4 2013, filed 10 Feb 2014.